EPOCH 43: BIOTECH MARKET RESEARCH ($SRPT)

Sarepta Therapeutics

This week we are featuring Sarepta Therapeutics and their upcoming Phase 3 EMBARK data in DMD. Given the uncertainty around the data we have chosen to highlight the event.  We anticipate high volatility around the most anticipated data readout remaining in 2023 - options pricing now suggests 40-60% move. 

Every Monday we are out with public biotech research, profiling biotech companies with near term catalysts. This will focus primarily on the major market moving biotech events such as data readouts from the major scientific conferences as well as potential regulatory approvals.

We will not offer specific trading advice (and we do not hold any publicly traded biotech equity), but rather flag emerging events that will likely materially drive stock prices (sometimes +/-100% in either direction).

Be sure to SUBSCRIBE to not miss.

HOW TO PLAY BIOTECH APPROVAL/DATA READOUTS ANNOUNCEMENTS

While biotech equities will move on news of announcement, often if there is high conviction in a positive read, a large run up ahead of the news will occur and the actual event turns into a sell the news event. Sometimes, investors wait for the actual event to make a long/short decision. And obviously if the news is disappointing (more often than not) the stock will tank.

This is not financial advice so you will have to make your own call on how to best play these events.

ALERT: Sarepta Therapeutics ($SPRT) Phase 3 EMBARK data in DMD

DATE: November 2023

IMPLIED VOLATILITY: +/- 40-60%

BACKGROUND: